Barclays Downgrades Pfizer (PFE) to Equalweight
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Price: $24.82 +2.35%
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 83
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 83
Join SI Premium – FREE
Barclays downgraded Pfizer (NYSE: PFE) from Overweight to Equalweight.
For more ratings news on Pfizer click here and for the rating history of Pfizer click here.
Shares of Pfizer closed at $18.33 yesterday.
For more ratings news on Pfizer click here and for the rating history of Pfizer click here.
Shares of Pfizer closed at $18.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer (PFE) PT Lowered to $35 at Guggenheim
- Erste Group Downgrades HSBC Holdings (HSBC) to Hold
- Wolfe Research Downgrades Intellia Therapeutics (NTLA) to Underperform
Create E-mail Alert Related Categories
Downgrades, Hot DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
